<DOC>
	<DOCNO>NCT00555906</DOCNO>
	<brief_summary>This Phase 1/2 study evaluate safety anti-tumor activity PD 0332991 combination VelcadeÂ® [ bortezomib ] dexamethasone patient receive least one previous treatment multiple myeloma .</brief_summary>
	<brief_title>An Investigational Drug , Palbociclib ( PD-0332991 ) , Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma . Patients Must Have Received Prior Treatment For Multiple Myeloma .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis symptomatic multiple myeloma define International Myeloma Working Group ( IMWGURC ) . Phase 1 : Relapsed relapsed/refractory myeloma least 1 previous treatment life expectancy 3 month . Phase 2 : Measurable ( defined IMWGURC ) disease least 1 previous treatment . History allogeneic stem cell transplant . Phase 2 : Prior bortezomib therapy allow demonstrated positive response , disease progression occur therapy . Must experience significant blood level change , e.g . low platelet , previous bortezomib therapy Prior radiation therapy &gt; 25 % bone marrow ( whole pelvis 25 % ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>